Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Brickell Biotech, Inc. stock logo
BBI
Brickell Biotech
$0.86
$2.21
$37.35
$6.75M0.02206,730 shs31,300 shs
BioCardia, Inc. stock logo
BCDA
BioCardia
$2.33
-2.5%
$2.24
$1.63
$4.66
$12.82M0.8195,310 shs195,587 shs
Genetic Technologies Limited stock logo
GENE
Genetic Technologies
$0.77
$0.77
$0.67
$3.77
$3.37M1.12N/AN/A
Organovo Holdings, Inc. stock logo
ONVO
Organovo
$3.94
$1.56
$21.96
$3.47M1.13617,505 shs243,634 shs
Windtree Therapeutics, Inc. stock logo
WINT
Windtree Therapeutics
$0.79
+8.2%
$0.71
$0.36
$737.44
$2.89M0.74.46 million shs79.13 million shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Brickell Biotech, Inc. stock logo
BBI
Brickell Biotech
0.00%0.00%0.00%0.00%0.00%
BioCardia, Inc. stock logo
BCDA
BioCardia
0.00%+13.27%+9.63%+20.71%-26.46%
Genetic Technologies Limited stock logo
GENE
Genetic Technologies
0.00%0.00%0.00%0.00%-4.38%
Organovo Holdings, Inc. stock logo
ONVO
Organovo
0.00%0.00%0.00%+22.16%-74.93%
Windtree Therapeutics, Inc. stock logo
WINT
Windtree Therapeutics
0.00%-18.89%+23.31%-46.32%-99.62%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Brickell Biotech, Inc. stock logo
BBI
Brickell Biotech
N/AN/AN/AN/AN/AN/AN/AN/A
BioCardia, Inc. stock logo
BCDA
BioCardia
3.5153 of 5 stars
3.83.00.00.03.82.50.6
Genetic Technologies Limited stock logo
GENE
Genetic Technologies
N/AN/AN/AN/AN/AN/AN/AN/A
Organovo Holdings, Inc. stock logo
ONVO
Organovo
N/AN/AN/AN/AN/AN/AN/AN/A
Windtree Therapeutics, Inc. stock logo
WINT
Windtree Therapeutics
3.1336 of 5 stars
3.05.00.00.03.80.01.3
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Brickell Biotech, Inc. stock logo
BBI
Brickell Biotech
0.00
N/AN/AN/A
BioCardia, Inc. stock logo
BCDA
BioCardia
3.50
Strong Buy$25.00972.96% Upside
Genetic Technologies Limited stock logo
GENE
Genetic Technologies
0.00
N/AN/AN/A
Organovo Holdings, Inc. stock logo
ONVO
Organovo
0.00
N/AN/AN/A
Windtree Therapeutics, Inc. stock logo
WINT
Windtree Therapeutics
2.00
Hold$350.0044,203.80% Upside

Current Analyst Ratings Breakdown

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Brickell Biotech, Inc. stock logo
BBI
Brickell Biotech
$4.64M0.00N/AN/A$9.75 per share0.00
BioCardia, Inc. stock logo
BCDA
BioCardia
$60K213.58N/AN/A$0.18 per share12.94
Genetic Technologies Limited stock logo
GENE
Genetic Technologies
$7.66M0.44N/AN/A$0.25 per share3.06
Organovo Holdings, Inc. stock logo
ONVO
Organovo
$122K0.00N/AN/A$0.02 per share0.00
Windtree Therapeutics, Inc. stock logo
WINT
Windtree Therapeutics
N/AN/AN/AN/A$38.99 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Brickell Biotech, Inc. stock logo
BBI
Brickell Biotech
-$39.47M-$13.52N/AN/AN/A-643.48%-156.10%-128.23%N/A
BioCardia, Inc. stock logo
BCDA
BioCardia
-$7.95M-$2.33N/AN/AN/AN/A-30,792.60%-223.06%8/12/2025 (Estimated)
Genetic Technologies Limited stock logo
GENE
Genetic Technologies
-$7.88MN/A0.00N/AN/AN/AN/A7/28/2025 (Estimated)
Organovo Holdings, Inc. stock logo
ONVO
Organovo
-$14.67M-$10.20N/AN/AN/A-10,151.64%-346.26%-187.53%N/A
Windtree Therapeutics, Inc. stock logo
WINT
Windtree Therapeutics
-$1.79M-$823.47N/AN/AN/AN/A-227.93%-56.46%8/18/2025 (Estimated)

Latest WINT, BBI, ONVO, GENE, and BCDA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
Windtree Therapeutics, Inc. stock logo
WINT
Windtree Therapeutics
-$39.00-$4.63+$34.37-$4.63$2.20 millionN/A
5/14/2025Q1 2025
BioCardia, Inc. stock logo
BCDA
BioCardia
-$0.39-$0.59-$0.20-$0.59N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Brickell Biotech, Inc. stock logo
BBI
Brickell Biotech
N/AN/AN/AN/AN/A
BioCardia, Inc. stock logo
BCDA
BioCardia
N/AN/AN/AN/AN/A
Genetic Technologies Limited stock logo
GENE
Genetic Technologies
N/AN/AN/AN/AN/A
Organovo Holdings, Inc. stock logo
ONVO
Organovo
N/AN/AN/AN/AN/A
Windtree Therapeutics, Inc. stock logo
WINT
Windtree Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Brickell Biotech, Inc. stock logo
BBI
Brickell Biotech
N/A
6.36
6.36
BioCardia, Inc. stock logo
BCDA
BioCardia
N/A
0.36
0.36
Genetic Technologies Limited stock logo
GENE
Genetic Technologies
0.01
0.88
0.83
Organovo Holdings, Inc. stock logo
ONVO
Organovo
N/A
0.72
1.72
Windtree Therapeutics, Inc. stock logo
WINT
Windtree Therapeutics
N/A
0.25
0.25

Institutional Ownership

CompanyInstitutional Ownership
Brickell Biotech, Inc. stock logo
BBI
Brickell Biotech
N/A
BioCardia, Inc. stock logo
BCDA
BioCardia
20.57%
Genetic Technologies Limited stock logo
GENE
Genetic Technologies
0.63%
Organovo Holdings, Inc. stock logo
ONVO
Organovo
8.23%
Windtree Therapeutics, Inc. stock logo
WINT
Windtree Therapeutics
29.33%

Insider Ownership

CompanyInsider Ownership
Brickell Biotech, Inc. stock logo
BBI
Brickell Biotech
4.53%
BioCardia, Inc. stock logo
BCDA
BioCardia
20.00%
Genetic Technologies Limited stock logo
GENE
Genetic Technologies
6.46%
Organovo Holdings, Inc. stock logo
ONVO
Organovo
3.72%
Windtree Therapeutics, Inc. stock logo
WINT
Windtree Therapeutics
0.33%
CompanyEmployeesShares OutstandingFree FloatOptionable
Brickell Biotech, Inc. stock logo
BBI
Brickell Biotech
162.87 million2.74 millionNot Optionable
BioCardia, Inc. stock logo
BCDA
BioCardia
405.50 million4.40 millionOptionable
Genetic Technologies Limited stock logo
GENE
Genetic Technologies
504.41 million4.53 millionOptionable
Organovo Holdings, Inc. stock logo
ONVO
Organovo
201.70 million14.79 millionOptionable
Windtree Therapeutics, Inc. stock logo
WINT
Windtree Therapeutics
303.66 million3.65 millionNot Optionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Brickell Biotech stock logo

Brickell Biotech NASDAQ:BBI

Brickell Biotech, Inc., a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company develops sofpironium bromide, which has completed Phase III clinical trials for the treatment of primary axillary hyperhidrosis; BBI-02, an oral DYRK1A inhibitor for the treatment of autoimmune and inflammatory diseases; and BBI-10, a covalent stimulator of interferon genes inhibitor for the potential treatment of autoinflammatory and rare genetic diseases, as well as next-generation kinase inhibitors. It has license and collaboration agreements with Carna Biosciences, Inc., Voronoi Inc., Bodor Laboratories, Inc. and Dr. Nicholas S. Bodor, and AnGes, Inc. The company was founded in 2009 and is headquartered in Boulder, Colorado.

BioCardia stock logo

BioCardia NASDAQ:BCDA

$2.33 -0.06 (-2.51%)
Closing price 04:00 PM Eastern
Extended Trading
$2.33 0.00 (0.00%)
As of 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. The company is also developing an allogeneic cells therapy platform, which is an investigational culture expanded bone marrow derived mesenchymal cell therapy in Phase I/II trial to treat ischemic heart failure and acute respiratory distress syndrome. In addition, it offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; and Morph deflectable guides and sheaths. The company has collaboration agreements with CellProthera in the development of ProtheraCytes, which is currently under Phase II trial for the treatment of acute myocardial infarction. BioCardia, Inc. is based in Sunnyvale, California.

Genetic Technologies stock logo

Genetic Technologies NASDAQ:GENE

$0.76 0.00 (0.00%)
As of 05/20/2025

Genetic Technologies Limited, a molecular diagnostics company, provides predictive genetic testing and risk assessment tools to help physicians manage people's health in the America, Canada, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. It operates through AffinityDNA, EasyDNA, and GeneType/Corporate segments. The company offers BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It also markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. In addition, the company offers various cancer risk assessment tests under the GeneType for Colorectal Cancer and GeneType for Breast Cancer brand names; and develops other risk assessment tests across a range of diseases, which include colorectal cancer, ovarian cancer, prostate cancer, coronary artery, type 2 diabetes, pancreatic cancer, melanoma, and atrial fibrillation. Further, it offers genetic testing services, including medical, animal, forensic, and plant testing. The company has research and collaboration agreements with the University of Melbourne for the development and commercialization of a novel colorectal cancer risk assessment test; and Memorial Sloan Kettering Cancer Center of New York and University of Cambridge, that assess the conflict among BRCA mutation carriers considering preventive surgery. Genetic Technologies Limited was incorporated in 1987 and is headquartered in Fitzroy, Australia.

Organovo stock logo

Organovo NASDAQ:ONVO

Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive 3D bioprinted human liver tissue with distinct hepatocellular and non-parenchymal cell compartments. The company was incorporated in 2007 and is headquartered in San Diego, California.

Windtree Therapeutics stock logo

Windtree Therapeutics NASDAQ:WINT

$0.79 +0.06 (+8.22%)
Closing price 04:00 PM Eastern
Extended Trading
$0.84 +0.05 (+6.20%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Windtree Therapeutics, Inc., a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company's lead product candidate is istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock. It also develops AEROSURF, an aerosolized KL4 surfactant that is in Phase 2b clinical trial to treat respiratory distress syndrome in premature infants; Surfaxin, a lyophilized KL4 surfactant, which is in Phase 2a clinical trial for the treatment of lung injury resulting from COVID-19; Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension; and oral and intravenous SERCA2a activator, which is in preclinical trial for the treatment of chronic and acute heart failure. In addition, it is developing aPKCi Inhibitor for the treatment of cutaneous malignancies and solid tumors that is in preclinical trials. Windtree Therapeutics, Inc. has a collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sale of a portfolio of potential KL4 surfactant products; license, development and commercialization agreement with Lee's Pharmaceutical (HK) Ltd. and Zhaoke Pharmaceutical (Hefei) Co. Ltd.; license agreement with Philip Morris USA, Inc. and Johnson & Johnson; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. The company was founded in 1992 and is headquartered in Warrington, Pennsylvania.